{"anticipatedPostingDate":"2028-09","calculatePct":false,"denomUnitsSelected":"Participants","description":"An AE was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily had a causal relationship with this treatment. TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. AEs included both SAEs and all other AEs. An AE should be classified as a serious SAE if it meets one of the following criteria: fatal, life threatening, requires or prolongs hospitalization, disabling/ incapacitating, congenital anomaly or birth defect, medically significant.","reportingStatus":"NOT_POSTED","timeFrame":"From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)","title":"Number of Participants With TEAEs: Through Study Completion","type":"OTHER_PRE_SPECIFIED"}